



EFFECT OF TERMINALIA CHEBULA (HARAD) FRUIT EXTRACT ON CARDIOTOXICITY IN 
STREPTOZOTOCIN INDUCED DIABETIC RATS 
Original Article 
 
SUPRIYA ROY1, TARIQUE MAHMOOD1*, HEFAZAT HUSSAIN SIDDIQUI1, PARAMDEEP BAGGA1,  
ARSHIYA SHAMIM1 
1Faculty of Pharmacy, Integral University, Dasauli, Kursi Road, Lucknow 226026, Uttar Pradesh, India 
Email: ansaritariq79@yahoo.co.in       
 Received: 09 Jun 2015 Revised and Accepted: 17 Jul 2015 
ABSTRACT 
Objective: The aim of the study was to explore the protective activity of Terminalia chebula fruit extract on cardiotoxicity in streptozotocin (STZ) 
induced diabetic rats. 
Methods: The animals were divided into eight groups of five each and were fed with high fat diet (HFD) except sham control, diabetic control and 
isoproterenol control. Diabetes was induced by administering single intraperitoneal (i. p.) injection of STZ (0.05 g/kg) in all groups except sham and 
isoproterenol control and was confirmed by testing blood glucose level after 48 h. Rats were pretreated with ethanolic extract of Terminalia chebula 
(0.25& 0.5 g/kg/d; per oral (p. o.)), pioglitazone (0.01 g/kg/d), carvedilol (0.002 g/kg/d) and normal saline throughout the study period (14 days). 
Cardiotoxicity was induced by the administrating two subcutaneous (s. c) injection of isoproterenol (ISO) (0.085 g/kg) at an interval of 24 h. 
Troponin was checked to confirm cardiotoxicity. The evaluation parameters include initial and final blood glucose level, change in body weight, food 
efficiency ratio (FER), heart weight-body weight ratio, biochemical estimations and histopathological studies. 
Results: Pretreatment with Terminalia chebula produced significant (p<0.01) decrease in blood glucose level and heart weight-body weight ratio. It 
significantly decrease the elevated activity of the cardiac marker enzymes, alanine transaminase (ALT), lactate dehydrogenase (LDH), creatinine 
kinase (CK-MB) (p<0.01), similar to the standard drug carvedilol in isoproterenol injected rats. Pretreatment with Terminalia chebula showed 
absence of troponin and lesser degree of necrosis, edema, and myofibrillar degeneration. 
Conclusion: Terminalia chebula has significant cardioprotective action against cardiotoxicity in STZ induced diabetic rats, which is comparable with 
standard drugs i.e., pioglitazone and carvedilol. 




Cardiotoxicity is a condition when there is damage to the heart 
muscle and dysfunction of heart electrophysiology. As a result of 
cardiotoxicity, the heart becomes weaker and is not as efficient in 
pumping and therefore circulating blood [1]. This may be due to 
chemotherapy drugs, complications from anorexia nervosa, adverse 
effects of heavy metals intake, or an incorrectly administered drug 
such as bupivacaine or other medications [2]. Cardiotoxicity, if 
severe, may lead to cardiomyopathy [1]. Myocardial infarction (MI), 
the medical term used for an event commonly known as a heart 
attack [3] represents permanent cellular injury and necrosis after a 
prolonged ischemic episode [4]. It happens when blood stops 
flowing properly to part of the heart and the heart muscle is injured 
due to not receiving enough oxygen [3]. Myocardial infarction is a 
leading cause of morbidity and mortality worldwide and presence of 
diabetes doubles the relative risk of MI as it increases the rate of 
atherosclerotic progression and adversely affects the lipid profile. 
Further, diabetes related changes in metabolic and autonomic 
functioning as well as increases in inflammatory and thrombotic 
signalling, compromise the ability of myocardial and vascular tissue 
to remodel after injury and to recover and sustain functionality [5].  
Streptozotocin (STZ) is well known for its selective pancreatic islet 
beta cell cytotoxicity and has been extensively used to induce 
diabetes in experimental rat model. It interferes with cellular 
metabolic oxidative mechanisms [6, 7]. Isoproterenol (ISO) is a beta 
adrenergic agonist that causes severe stress in myocardium and 
necrotic lesions in heart muscles [8] and marked inotropic and 
chronotropic action results in loss of function and integrity of 
myocardial membrane [9]. Myocardial infarction induced by ISO in 
rats has been shown to be accompanied by hyperglycemia and a 
significant increase in the levels of serum marker enzymes [10, 11].  
Traditional medicines are now commonly used in treating and 
preventing specific ailments and are considered to play a significant 
role in health care. Indeed, phytomedicines are beginning to link 
traditional and modern medicines [12]. 
Terminalia chebula is extensively used in ayurveda, siddha, unani 
and homeopathic medicines in India [13] and is chief ingredient of 
Triphala, a polyherbal preparation used as laxative in chronic 
constipation, detoxifying agent of the colon and food digestive 
problems. It also stimulates appetite and is useful in treating cancer. 
Triphala is prescribed as a cardio tonic [14]. 
Terminalia chebula has been proved to be a good hypoglycemic and 
cardioprotective agent, so it was worth to explore its protective 
effect against diabetes induced cardiac complications, as it directly 
related to present clinical condition. 
MATERIALS AND METHODS 
Collection and authentification of plant material 
Dried fruits of Terminalia chebula were purchased from the local 
market of Lucknow. The plant material was authenticated by a 
botanist of National Botanical Research Institute (NBRI), Lucknow. A 
voucher specimen number NBRI/CIF/407/2013 has been deposited 
at the herbarium of faculty of pharmacy, Integral University, 
Lucknow, India. 
Preparation of plant extract 
Terminalia chebula fruits were dried under shade and milled to 
obtain a fine powder. Powder of Terminalia chebula fruits was 
accurately weighed around 250 g for extraction. Extraction from 
powder was done by cold maceration process for 72 h by using five 
time quantity of 90% ethanol and was filtered to get extract of 
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solvent. Collected extract was evaporated to get soft extract. Soft 
extract collected was weighed [15, 16]. 
Drugs and chemicals 
Isoproterenol hydrochloride was purchased from Sigma Aldrich, U. S. 
A., normal saline (0.9%) from Albert David Limited, Ghaziabad and 
streptozotocin from M. P. bio medicals, Pune. Carvedilol and 
pioglitazone were taken as marketed preparations of Sun Pharma 
limited, brand name was cardivas and pioglit respectively, procured 
from the local market. The Serum ALT diagnostic kit was purchased 
from Span Diagnostics, Surat and Serum CK-MB and LDH diagnostic 
kits from Merck Specialities Private Limited. Troponin I kit was 
obtained from Roche Diagnostic. All chemicals used were of 
analytical grade. 
Experimental animals 
Male Sprague dawley rats (l50-200 g) were used for the study. They 
were housed five each in sanitized polypropylene cages containing 
paddy husk as bedding under standard laboratory conditions at 
room temperature (23 °C±2 °C) with 12 h light/dark cycle. The 
animals were randomized into experimental and control groups.  
They had free access to standard pellets as basal diet and water ad 
libitum. Ethical clearance was obtained from Institutional Animal 
Ethical Committee (IAEC). The approval no. is IU/Pharm/M. 
Pharm/IAEC/14/02 Faculty of pharmacy Integral University, 
Dasauli, P. O. Basha Kursi Road; Lucknow–226026 (U. P). 
Experimental protocol 
Induction of diabetes mellitus 
Streptozotocin (0.05 g/kg, i. p.) was administered at the 4th day of 
study after 24 h fasting in every group except sham and 
isoproterenol control. Diabetes was confirmed after 48 h of 
streptozotocin injection by collecting blood samples from tail tip 
using a blood glucometer. The rats with fasting blood glucose level 
above 2.5 g/l were considered diabetic and were used in the 
experiment [17-19].  
Induction of cardiotoxicity 
Cardiotoxicity was induced by two consecutive injection of 
isoproterenol (0.085 g/kg, s. c.) at an interval of 24 h on the 12th and 
13th day of study [20]. 
Preparation of high fat diet (HFD) 
High fat diet was prepared according to the composition mentioned 
by Vijaya et al. [21]. 
Treatment protocol 
All diabetic rats were divided into eight groups of five animals each 
for which the dosing and treatment schedule is as follows  
Group I–Normal control (Sham) 
Rats were administered with normal saline instead of streptozotocin 
and fed with normal pellet diet (NPD) throughout the study period. 
Group II–Diabetic control (D-NPD) 
Rats were administered with STZ (0.05 g/kg, i. p.) and fed with NPD 
throughout the study period (14 d) and administered with 
isoproterenol (0.085 g/kg, s. c) at an interval of 24 h on the 12th and 
13th day of study. 
Group III–Diabetic high fat diet Control (D-HFD) 
Rats were administered with STZ (0.05 g/kg, i. p.) and fed with HFD 
along with NPD throughout the study period (14 d) and 
administered with isoproterenol (0.085 g/kg, s. c) at an interval of 
24 h on the 12th and 13th day of study. 
Group IV–Isoproterenol challenged (NPD-C-I) 
Rats were fed with NPD throughout the study period (14 d) and 
administered with isoproterenol (0.085 g/kg, s. c) at an interval of 
24 h on the 12th and 13th day of study. 
Group V–Pioglitazone treated (0.01 g/kg) 
Rats were administered with STZ (0.05 g/kg, i. p.) and fed with HFD 
along with NPD and pretreated with pioglitazone (0.01 g/kg/d; p. o.) 
throughout the study period (14 d) and then administered with 
isoproterenol (0.085 g/kg, s. c) at an interval of 24 h on the 12th and 
13th day of study. 
Group VI–Carvedilol treated (0.002 g/kg) 
Rats were administered with STZ (0.05 g/kg, i. p.) and fed with HFD 
along with NPD and pretreated with carvedilol (0.002 g/kg/d; p. o.) 
throughout the study period (14 d) and then administered with 
isoproterenol (0.085 g/kg, s. c) at an interval of 24 h on the 12th and 
13th day of study. 
Group VII–T. chebula extract treated (0.25 g/kg) 
Rats were administered with STZ (0.05 g/kg, i. p.) and fed with HFD 
along with NPD and pretreated with ethanolic extract of T. chebula 
(0.25 g/kg/d; p. o.) throughout the study period (14 d) and then 
administered with isoproterenol (0.085 g/kg, s. c) at an interval of 
24 h on the 12th and 13th day of study. 
Group VIII–T. chebula extract treated (0.5 g/kg) 
Rats were administered with STZ (0.05 g/kg, i. p.) and fed with HFD 
along with NPD and pretreated with ethanolic extract of T. chebula 
(0.5 g/kg/d; p. o.) throughout the study period (14 d) and then 
administered with isoproterenol (0.085 g/kg, s. c) at an interval of 
24 h on the 12th and 13th day of study. 
At the end of the study, the animals were weighed and then 
sacrificed with the high dose of diethyl ether. Blood samples 
were collected by cardiac puncture/retro orbital plexus and 
were allowed to clot at room temperature. The serum was then 
separated by centrifugation at 3000 rpm at 30 °C for 15 min and 
was used for estimations of cardiac marker enzymes. The heart 
was excised immediately and rinsed with ice cold saline, blotted 
with filter paper and weighed. Photographs were taken for gross 
examination and a portion of the heart of different groups were 
cut and homogenized in ice chilled phosphate buffer. Rest of the 
heart was kept in 10% formalin solution for histopathological 
studies [20, 22-25]. 
Estimations 
Fasting blood glucose was estimated at the beginning of study on 
day 0 as well as at the end of the study on day 14 by using 
glucometer. Body weight gain was calculated according to the 
formula: final body weight-initial body weight. Food efficiency ratio 
was calculated as: total body weight/total food intake. 
After the sacrifice of animal, the heart was excised immediately and 
rinsed with ice cold saline, blotted with filter paper and weighed. 
Heart weight-body weight ratio was calculated according to the 
formula: heart weight/final body weight * 103.  
Grading of heart was done by observing the morphological changes 
seen by naked eyes according to following criteria:  
Grade 0 = No Lesion, Grade 1= Inflammation, redness, capillary 
dilations, Grade 2 = Edema, yellowish ventricle portion, Grade 3 = 
Atrium & ventricle turns yellow, scar formation, Grade 4 = Diffuse 
heart, absolute scar formation, increased necrosis portion. 
Troponin was checked by ready to use kits from Roche diagnostics 
after 4-5 h of second isoproterenol injection and other cardiac 
marker enzymes; alanine transaminase (ALT), lactate 
dehydrogenase (LDH), and creatine kinase-MB (CK-MB) were 
estimated by commercially available kits of span cogent diagnostics 
and merck specialities respectively, according to the procedure 
given on assay leaflet provided with the kits. 
At the end of study, the heart was isolated, washed with ice cold 
saline and the tissue was fixed in 10% buffered neutral formalin 
solution. Histopathological studies were done from RS Diagnostics 
centre, Lucknow. Hematoxylin and eosin stain was used. The slides 
were observed under the light microscope and photomicrographs 
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were taken on 10 and 40x. The study includes an evaluation of 
myocardial fibrosis, vascular lesions and measurement of 
myocardial cell size [17-19, 26]. 
Statistical analysis 
Data was expressed as mean±standard deviation (SD, n = 5). 
Statistical analysis was performed using one-way analysis of 
variance (ANOVA) followed by Turkey’s Kramer comparison test 
with the aid of Graph Pad prism in stat software (version 5.0, USA). 

















































Fig. 1: Final blood glucose level 
All values are expressed as mean±standard error of the mean (SEM) 
calculated by one way ANOVA (n=5). * = p<0.01when comparison is 
done between Sham and D-NPD, D-NPD and D-HFD, D-HFD and 
pioglitazone, D-HFD and T. chebula (T. C.) (0.25 g/kg), D-HFD and T. 









































Fig. 2: Heart weight-body weight ratio 
*= p<0.01when comparison is done between Sham and DNPD, DNPD 
and D-HFD, D-HFD and carvedilol, DHFD and T. chebula (0.25 g/kg), 
D-HFD and T. chebula (0.05 g/kg) as calculated by one way ANOVA 
followed by Tukey’s t-test. 
 
 
Fig. 3: Assessment and grading of heart (a) Sham (b) D-NPD (c) 
D-HFD (d) NPD-C-I (e) Pioglitazone (f) Carvedilol (g) Terminalia 
chebula (0.25 g/kg) (h) Terminalia chebula (0.05 g/kg)
Table 1: Food efficiency ratio (FER) 
S. No. Groups 1 2 3 4 5 Mean±SEM 
Sham 5.5 5.6 5.7 6.2 6.7 5.94±0.22 
D-NPD 2.21 2.03 1.88 1.85 2.28 2.05*±0.08 
D-HFD 3.83 3.56 4.21 3.97 4.16 3.94*±0.11 
NPD-C-I(0.085 g/kg) 4.26 4.37 4.57 4.81 4.70 4.54*±0.10 
Pioglitazone(0.01 g/kg) 6.74 6.55 7.02 6.96 7.50 6.95*±0.15 
Carvedilol(0.002 g/kg) 3.07 3.00 3.54 3.26 3.45 3.26*±0.10 
T. chebula(0.25 g/kg) 4.66 4.23 5.27 4.87 5.21 4.84*±0.19 
T. chebula(0.05 g/kg) 4.72 4.68 4.85 4.55 5.12 4.78*±0.09 
All values are expressed as mean±SEM calculated by one way ANOVA (n=5). *=p<0.01when comparison is done between Sham and DNPD, DNPD 
and D-HFD, D-HFD and pioglitazone, DHFD and T. chebula (0.25 g/kg), D-HFD and T. chebula (0.05 g/kg) followed by Tukey’s t-test. 
 
Gross examination of heart 
Table 2: Assessment and grading of heart 
 Groups Grading of cardiac damage 
Sham Grade 0 
Diabetic control (D-NPD) Grade 3 
Diabetic-high fat diet Control(D-HFD) Grade 4 
Isoproterenol control (NPD-C-I) Grade 3 
Pioglitazone(0.01g/kg) Grade 2 
Carvedilol (0.002 g/kg) Grade 1 
T. chebula extract 1 (0.25 g/kg) Grade 3 
T. chebula extract 2 (0.05 g/kg) Grade 2 
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Fig.4: Cardiac marker enzymes (a) Alanine Aminotransferase (ALT) (b) Creatinine kinase-myoglobulin (CK-MB) (c) Lactate 
dehydrogenase (LDH) 
*= p<0.01when comparison is done between Sham and DNPD, DNPD and D-HFD, D-HFD and carvedilol, DHFD and T. chebula (0.25 g/kg), D-HFD 
and T. chebula (0.05 g/kg) as calculated by one way ANOVA (n = 5) followed by Tukey’s t-test. 
 
Troponin–I 
Table 3: Troponin-I 
S. No. Groups 1 2 3 4 5 
Sham -ve -ve -ve -ve -ve 
D-NPD +ve +ve +ve +ve +ve 
D-HFD +ve +ve +ve +ve +ve 
NPD-C-I(0.085g/kg) +ve +ve +ve +ve +ve 
Pioglitazone(0.01 g/kg) +ve +ve +ve +ve +ve 
Carvedilol(0.002 g/kg) -ve -ve +ve -ve -ve 
T. chebula(0.25 g/kg) +ve +ve +ve -ve -ve 
T. chebula(0.05 g/kg) -ve -ve -ve +ve +ve 
Where+ve denotes presence of enzyme and–ve denotes absence of enzyme 
 
Histopathological studies 
Photomicrographs of rat heart of sham control group revealed that 
the muscle fibres was compactly arranged with minimum interstitial 
tissue. There was no muscular hypertrophy or evidences of necrosis. 
Photomicrographs of rat heart of D-NPD, D-HFD and NPD-I-C groups 
showed that the muscle fibres was loosely arranged with 
fragmentation and increased interstitial tissue. Photomicrographs of 
rat heart of pioglitazone, carvedilol and Terminalia chebula (0.05 
g/kg) group showed that the bundles of muscle fibres were 
compactly arranged with minimum interstitial tissue whereas 
Terminalia chebula (0.25 g/kg) group showed that the muscle fibres 
were loosely arranged with fragmentation and increased interstitial 
tissue. H&E stain was used.  
All photographs were taken on 10 and 40 x (fig. 5). 
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Fig. 5: Photomicrographs of histopathology of rat’s heart of different groups (a) Sham (b) D-NPD (c) D-HFD (d) NPD-C-I (e) Pioglitazone (f) 
Carvedilol (g) Terminalia chebula (0.25 g/kg) (h) Terminalia chebula (0.05 g/kg) 
 
DISCUSSION 
Myocardial infarction, commonly known as a heart attack, is a 
leading cause of morbidity and mortality worldwide and presence of 
diabetes doubles the relative risk of MI as it increases the rate of 
atherosclerotic progression and adversely affects the lipid profile. 
Myocardial cell protection and prevention of cell ischemia or 
necrosis have been therapeutics targets for a long time [27]. 
Traditional medicines are now commonly used in treating and 
preventing specific ailments and are considered to play a significant 
role in health care as current treatment has only a limited impact on 
survival and annual cost. Terminalia chebula proved to be a good 
hypoglycemic and cardioprotective agent [28, 29]. The prime 
objective of the present study was to explore the cardioprotective 
activity of Terminalia chebula against isoprenaline induced 
myocardial necrosis in diabetic as well as non diabetic rats. 
Experimental diabetes was produced by low dose of STZ (0.05 g/kg) 
combined with high fat diet intake. High fat diet induces insulin 
resistance and an injection of low dose STZ makes partial 
dysfunction of beta cell to suppress insulin secretion, which works 
as a compensation to insulin resistance [26, 30]. Cardiotoxicity was 
induced by administering isoproterenol (0.085 g/kg, s. c) on the 12th 
and 13th day of study at an interval of 24 h [20]. 
Injection of STZ with 2 w of dietary manipulation, significantly 
(p<0.01) increased blood glucose level in diabetic high fat diet 
control group (D-HFD), thus producing frank hyperglycemia. 
Pretreatment with high dose of Terminalia chebula (0.05 g/kg) 
produced significant (p<0.01) decrease in the blood glucose level 
where as pretreatment with low dose of Terminalia chebula (0.25 
g/kg) caused small but statistically significant decrease in blood 
glucose level when compared to D-HFD.  
In addition, the feeding of HFD for a period of 2 w caused significant 
(p<0.01) increase in body weight. Pretreatment with Terminalia 
chebula produced statistically significant decrease in body weight. 
Also, food efficiency ratio was significantly improved in both 
pretreated Terminalia chebula extract group (p<0.01) when 
comparison is made with D-HFD group. 
In the present study, Terminalia chebula significantly prevented 
isoproterenol and diabetes induced myocardial damage and 
hypertrophy in diabetic rats which were clearly indicated by various 
estimation parameters that include physical/morphological 
parameters, biochemical as well as histopathological parameters.  
Isoproterenol control showed more significant myocardial damage 
when compared to normal control rats as the grading shifts from 
zero to three, but the damage was most significant (grade 4) in 
diabetic high fat diet control group (D-HFD), as it was accentuated 
by diabetes. High dose of Terminalia chebula extract (0.05 g/kg) 
showed more significant cardioprotective activity when compared 
to D-HFD group as it show the shift from grade 4 to grade 2 while 
low dose of test extract (0.25 g/kg) showed less significant 
cardioprotective activity as the grade shift from four to three when 
compared to D-HFD group. The heart weight body weight ratio is a 
very important parameter of cardiac hypertrophy. High dose of 
Terminalia chebula extract showed the significant protective effect 
(p<0.01) when compared to D-HFD control group while low dose of 
Terminalia chebula does not show significant cardioprotection 
against isoproterenol induced cardiac damage (p<0.01) 
Myocardial enzymes CK-MB, LDH and AST are biochemical 
indicators of myocardial injury; troponin-I/T, being the gold marker 
of cardiac damage. Once myocardium is damaged, they are released 
into the extra cellular fluid that serves as the diagnostic enzyme 
marker of myocardial damage tissue [31]. Levels of all the enzymes 
were significantly elevated in the D-HFD group. Troponin test was 
positive in D-HFD group. Pretreatment with high dose of Terminalia 
chebula protected diabetic rats against cardiac injury, which was 
evidenced by negative troponin test and significant decreased 
myocardial enzymes {ALT (p<0.01), LDH (p<0.01), CK-MB (p<0.01)} 
when compared to D-HFD group while low dose of Terminalia 
chebula extract (0.25 g/kg) doesn’t show significant cardioprotective 
effect{(ALT (p<0.01), CK-MB (p<0.01), LDH (p<0.01) }, against 
isoproterenol induced damage. All the results of test extract were 
compared and found similar to the clinically established standard 
drugs pioglitazone (0.01 g/kg) and carvedilol (0.002 g/kg).  
These results were also confirmed by the histopathological studies. 
Photomicrographs of rat heart of sham control group revealed that 
the muscle fibres was compactly arranged with minimum interstitial 
tissue. There was no muscular hypertrophy or evidences of necrosis. 
Photomicrographs of rat heart of D-NPD, D-HFD and NPD-I-C groups 
showed that the muscle fibres was loosely arranged with 
fragmentation and increased interstitial tissue. Photomicrographs of 
rat heart of pioglitazone, carvedilol and Terminalia chebula (0.05 
g/kg) group showed that the bundles of muscle fibres were 
compactly arranged with minimum interstitial tissue whereas 
Terminalia chebula (0.25 g/kg) group showed that the muscle fibres 
were loosely arranged with fragmentation and increased interstitial 
tissue. Thus, histopathology report revealed that ISO and diabetes 
caused potent myocardial damage when compared to sham and 
pretreated group which showed significant cardioprotection as 
revealed by photomicrographs of rat’s heart. 
CONCLUSION 
The present study concludes with few observations and results. The 
first aspect of the present study is that high fat diet al. ong with STZ 
induced diabetes is a very suitable, potent and short term model for 
evaluating the cardiotoxicity in diabetic rats. The second aspect of 
the study is isoproterenol causes cardiotoxicity more potently in 
diabetic rats as compared to non diabetic rats which is clearly 
parallel to the clinical existence. The third aspect is related to the 
protective effect of alcoholic extract of Terminalia chebula which 
shows potent protection at high dose (0.05 g/kg) against 
isoproterenol-induced cardiotoxicity in STZ induced non-genetic 
type II diabetic rats which is comparable to clinically established 
standard drugs i.e., pioglitazone (0.01 g/kg) and carvedilol (0.002 
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g/kg). This may provide an incentive for proper clinical evaluation of 
the plant as the medicinal agent in the treatment of diabetes, 
myocardial infarction, and perhaps other cardiovascular disorders. 
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